Zephyr Valves & Bronchoscopic Lung Volume Reduction

This guide explains what bronchoscopic lung volume reduction (BLVR) with endobronchial valves is, who it suits, what the procedure and recovery involve, and where physiotherapy fits before and after. A clinician evidence summary follows the patient section — jump to it.

Why trapped air is the problem

Emphysema destroys the elastic walls between air sacs. The lung loses its spring, so air goes in but struggles to come out. Over time the worst-affected lobes become permanently over-inflated — hyperinflation — which:

• pushes the diaphragm flat, taking away its most powerful range of movement;
• squeezes the healthier lung tissue that is still capable of gas exchange;
• forces you to start each breath with your lungs already part-full, so the work of breathing climbs steeply with activity;
• makes breathlessness worse than the airflow numbers alone would predict.

Bronchodilators, pulmonary rehabilitation and breathing retraining all help you live better with hyperinflation. Volume reduction is different: it physically removes the over-inflated lobe from the equation.

What Zephyr valves are, and what they do

A Zephyr valve is a small silicone-and-nitinol one-way valve, about the size of a grain of rice, placed inside an airway. Several (typically three to five) are placed in the airways feeding one target lobe. The valve closes on the way in and opens on the way out, so:

Who is suitable

Valves work only in a narrow group, and the assessment is deliberately thorough. A specialist respiratory team decides — usually at a multidisciplinary meeting — using breathing tests, a high-resolution CT and often a measurement taken during bronchoscopy.^1,2

An important note about expectations. Valves do not cure emphysema and do not stop it progressing. They change the mechanics of breathing. Some people improve markedly, some modestly, and some not at all — which is why the team spends so long on selection before offering the procedure.

What happens — the procedure and the hospital stay

What the results look like

In the pivotal trial of Zephyr valves in carefully selected patients, average results at 12 months compared with continued medical care were:¹

Averages hide individuals. Ask your specialist what the realistic range is for your CT and lung volumes.

Where physiotherapy fits

Before the procedure

• Pulmonary rehabilitation is part of the pathway, not an optional extra. Programmes are expected before valves are offered, and fitter patients tolerate the anaesthetic and the recovery better.²
• Airway clearance and sputum control. A wet, poorly cleared chest raises infection risk and can rule the procedure out. We optimise clearance before you go in — see Principles of Airway Clearance.
• Inhaler technique and adherence. Valves are offered when medical therapy is optimised; technique errors quietly undermine that. See Getting Your Inhaler Technique Right.
• Breathing pattern and pacing. Practising pursed-lip breathing, recovery positions and pacing before surgery means you already own the tools when you need them afterwards.
• Smoking cessation and nutrition support — both are prerequisites and both change outcome. See Smoking Cessation.

After the procedure

• Early mobilisation in hospital, guided by the treating team, with close attention to any change in breathlessness or pain.
• Airway clearance is re-planned, not simply resumed. The target lobe is deliberately collapsed, so clearance now targets the remaining lung. Techniques that generate high pressures or vigorous coughing are re-introduced cautiously in the early weeks, in consultation with the treating respiratory team — there is no benefit in stressing a fresh valve or a lung at risk of air leak.
• Positive-pressure devices and NIV need a specialist decision. If you use continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP) or a positive expiratory pressure (PEP) device, ask the team explicitly when and how to restart. Do not resume on assumption.
• Pulmonary rehabilitation again, once cleared. This is where the mechanical gain becomes a functional gain: the valves give you room to breathe, rehabilitation converts it into walking distance, stair tolerance and confidence.
• Ongoing review. Benefit can fade if a valve migrates or a new exacerbation pattern develops; we track walking distance and symptom scores over time and flag changes to your specialist.

Other volume-reduction options

Evidence summary — endobronchial valves in severe emphysema

Mechanism and rationale. BLVR targets static hyperinflation rather than airflow obstruction per se. Target-lobe atelectasis reduces residual volume, improves diaphragm configuration and length–tension relationship, and decompresses adjacent, better-perfused parenchyma. The magnitude of symptomatic benefit tracks the degree of target-lobe volume reduction more closely than the change in FEV₁.

• STELVIO (randomised, patients selected by Chartis-confirmed absence of collateral ventilation) reported between-group improvements in FEV₁, FVC and 6-minute walk distance at 6 months that are among the largest seen with any intervention in severe chronic obstructive pulmonary disease (COPD).³
• TRANSFORM (heterogeneous emphysema, no collateral ventilation) reported a markedly higher proportion of patients achieving a ≥12% FEV₁ improvement at 3 months versus standard care, with parallel gains in SGRQ and six-minute walk distance (6MWD).⁴
• LIBERATE, the 12-month pivotal trial, confirmed durability to one year: mean FEV₁ improvement of about 18% over control, +39 m 6MWD, −7.1 points SGRQ, with target-lobe volume reduction the key mediator. Pneumothorax occurred in roughly a quarter of patients, concentrated in the first days.¹
• EMPROVE demonstrated comparable benefit for the Spiration valve system, supporting a class effect for one-way valves in appropriately selected disease.⁸
• NETT remains the reference point for surgical LVRS, identifying upper-lobe-predominant disease with low baseline exercise capacity as the group with a survival advantage, and a high-risk subgroup (FEV₁ ≤20% predicted with either homogeneous disease or DL_CO ≤20%) in whom intervention increased mortality.⁵

• Physiology: severe airflow obstruction with substantial static hyperinflation; a high residual volume is the entry criterion that matters most. Trial thresholds have varied, so treat the referral centre's protocol as definitive rather than quoting a single cut-off.
• Morphology: quantitative CT for emphysema distribution and fissure integrity; a complete fissure predicts absent collateral ventilation, and borderline cases proceed to Chartis assessment at bronchoscopy.
• Exclusions that matter in practice: frequent infective exacerbations, clinically significant bronchiectasis or high sputum burden in the target lobe, significant pulmonary hypertension, unstable cardiac disease, DL_CO at the extreme low end, giant bullae, and continued smoking.
• Guideline position: current international COPD strategy documents support considering BLVR or LVRS in selected patients with advanced emphysema who remain symptomatic despite optimised pharmacological and non-pharmacological management, including pulmonary rehabilitation.^2,9

Pneumothorax is the dominant early adverse event, most often within 72 hours and mechanistically linked to rapid target-lobe deflation with expansion of adjacent lung. Hence the standard minimum three-night inpatient observation and the emphasis on patient education at discharge. Other events include COPD exacerbation, pneumonia distal to the valve, granulation tissue, valve migration or expectoration, and haemoptysis. Valve removal is feasible bronchoscopically and is part of the management algorithm for persistent air leak, infection or non-response.^1,4

• Pre-habilitation: pulmonary rehabilitation is a pathway prerequisite and a legitimate diagnostic test of remediable deconditioning. Document walking distance and symptom scores before referral — they become the comparator for judging response.
• Airway clearance re-planning: the target lobe is intentionally atelectatic; clearance is directed at the remaining lung. Re-introduce techniques that generate high transpulmonary pressures — vigorous manual techniques, PEP/oscillating devices, IPPB, huff-heavy regimens — only in consultation with the treating team, given the air-leak risk in the early post-procedure period. There is no high-quality trial guiding timing; practice is properly conservative and centre-specific.
• NIV and CPAP: resumption after valve placement is a specialist decision. Ask, document the answer, and do not assume the pre-procedure prescription still applies.
• Post-procedure rehabilitation: the mechanical change creates headroom; supervised exercise training converts it into function. Programme entry should be timed with the respiratory team, then progressed conventionally with attention to dynamic hyperinflation, pacing and inspiratory muscle load.
• Surveillance role: physiotherapists often see these patients most frequently. A fall in walking distance, a new sustained rise in breathlessness, or a change in sputum pattern warrants a prompt message back to the referring physician — valve migration and loss of atelectasis are both retrievable if identified.

• No randomised evidence defines the safe timing or intensity of airway-clearance techniques or positive-pressure therapy after valve placement.
• Optimal timing, content and dose of post-BLVR pulmonary rehabilitation is unestablished, as is whether inspiratory muscle training adds value once diaphragm geometry improves.
• Long-term durability beyond several years, and the effect of subsequent exacerbations on maintained atelectasis, remain incompletely characterised.
• Patient-selection thresholds for residual volume and DL_CO continue to be refined, and real-world cohorts report outcomes below trial averages — relevant when counselling expectations.